Histaover LM Syrup is a combination medication containing Levocetirizine and Montelukast, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, rhinorrhea, and itching. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, mitigating airway inflammation and bronchoconstriction commonly associated with allergic reactions and asthma. The synergistic effect of these active ingredients provides comprehensive relief from allergic symptoms by targeting multiple pathways involved in the allergic response. Histaover LM Syrup is particularly beneficial in pediatric and adult patients requiring both antihistaminic and anti-inflammatory actions. It is administered orally, with dosing tailored according to age and clinical condition. Common adverse effects may include headache, fatigue, and gastrointestinal disturbances, though the combination is generally well tolerated. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Histaover LM Syrup should be used under medical supervision to ensure optimal therapeutic outcomes and to monitor for potential drug interactions or side effects.